205442-89-3

Basic information

• Product Name: (3S,5R,7AR)-5-(BENZOTRIAZOL-1-YL)-3-PHENYL[2,1-B]OXAZOLOPYRROLIDINE
• Synonyms: 1H-Benzotriazole,1-(hexahydro-3-phenylpyrrolo[2,1-b]oxazol-5-yl)-, [3S-(3a,5a,7aa)]-
• CAS NO: 205442-89-3
• Molecular Formula: C₁₈H₁₈N₄O
• Molecular Weight: 306.367
• Mol File: 205442-89-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3S,5R,7AR)-5-(BENZOTRIAZOL-1-YL)-3-PHENYL[2,1-B]OXAZOLOPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,5R,7AR)-5-(BENZOTRIAZOL-1-YL)-3-PHENYL[2,1-B]OXAZOLOPYRROLIDINE(205442-89-3)
• EPA Substance Registry System: (3S,5R,7AR)-5-(BENZOTRIAZOL-1-YL)-3-PHENYL[2,1-B]OXAZOLOPYRROLIDINE(205442-89-3)

Safety Data

• Hazardous Substances Data: 205442-89-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3S,5R,7AR)-5-(BENZOTRIAZOL-1-YL)-3-PHENYL[2,1-B]OXAZOLOPYRROLIDINE is used as a potential candidate for drug development due to its unique structure and the possibility of targeting specific biological pathways, which may be beneficial in creating new therapeutic agents.
Used in Cosmetics Industry:
(3S,5R,7AR)-5-(BENZOTRIAZOL-1-YL)-3-PHENYL[2,1-B]OXAZOLOPYRROLIDINE is used as a UV-absorbing agent in sunscreen and sunblock formulations, capitalizing on the potential UV-absorbing properties conferred by the benzotriazol-1-yl and phenyl groups present in its structure.
Further research and testing are required to fully explore and understand the potential uses and properties of this compound, as its current applications are based on its structural features and conjecture of its possible biological activity.

Upstream product

• 95-14-7 1,2,3-Benzotriazole 
• 638-37-9 butanedial 
• 20989-17-7 (2S)-2-phenylglycinol 
• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 2935-35-5 (S)-2-phenylglycine 
• 2592-95-2 benzotriazol-1-ol 

Downstream Products

• 205442-90-6 (3S,5S,7aR)-3,5-diphenylhexahydropyrrolo<2,1-b><1,3>oxazole 
• 205442-97-3 (2S)-2-(2R,5R)-2,5-dimethyltetrahydro-1H-1-pyrrolyl-2-phenylethan-1-ol 
• 205442-92-8 (2S)-2-(2R,5S)-2,5-dimethyltetrahydro-1H-1-pyrrolyl-2-phenylethan-1-ol 
• 222314-39-8 (3S,5S,7aR)-5-(2-Methyl-allyl)-3-phenyl-hexahydro-pyrrolo[2,1-b]oxazole 
• 205442-98-4 (S)-2-((2R,5R)-2,5-Dipropyl-pyrrolidin-1-yl)-2-phenyl-ethanol 
• 205442-93-9 (S)-2-((2S,5R)-2,5-Dipropyl-pyrrolidin-1-yl)-2-phenyl-ethanol 
• 205442-99-5 (S)-2-((2R,5R)-2,5-Dipentyl-pyrrolidin-1-yl)-2-phenyl-ethanol 
• 205442-94-0 (S)-2-((2S,5R)-2,5-Dipentyl-pyrrolidin-1-yl)-2-phenyl-ethanol 
• 205443-00-1 (S)-2-((2R,5R)-2,5-Diphenethyl-pyrrolidin-1-yl)-2-phenyl-ethanol 
• 205442-95-1 (S)-2-((2R,5S)-2,5-Diphenethyl-pyrrolidin-1-yl)-2-phenyl-ethanol 
• 1187481-40-8 (2S)-2-[(2R,5S)-2,5-dibenzyltetrahydro-1H-pyrrol-1-yl]-2-phenylethanol 
• 1436696-58-0 C₃₀H₃₃NO₅ 
• 1436696-32-0 C₃₀H₃₃NO₅ 
• 1436696-61-5 C₃₂H₄₁NO₅ 

Relevant articles and documents

Pyrrolidine analogs of GZ-793A: Synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2)

Central heterocyclic ring size reduction from piperidinyl to pyrrolidinyl in the vesicular monoamine transporter-2 (VMAT2) inhibitor GZ-793A and its analogs resulted in novel N-propane-1,2(R)-diol analogs 11a-i. These compounds were evaluated for their affinity for the dihydrotetrabenazine (DTBZ) binding site on VMAT2 and for their ability to inhibit vesicular dopamine (DA) uptake. The 4-difluoromethoxyphenethyl analog 11f was the most potent inhibitor of [3H]-DTBZ binding (Ki = 560 nM), with 15-fold greater affinity for this site than GZ-793A (Ki = 8.29 μM). Analog 11f also showed similar potency of inhibition of [3H]-DA uptake into vesicles (Ki = 45 nM) compared to that for GZ-793A (Ki = 29 nM). Thus, 11f represents a new water-soluble inhibitor of VMAT function.

SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS

Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.

Asymmetric syntheses of 2-substituted and 2,5-disubstituted pyrrolidines from (3S,5R,7aR)-5-(benzotriazol-1-yl)-3-phenyl[2,1-b]oxazolopyrrolidine

Benzotriazole, 2,5-dimethoxytetrahydrofuran, and (S)-phenylglycinol in one step gave 80% of (3S, 5R,7aR)-5-(benzotriazol-1-yl)-3-phenyl-[2,1- b]oxazolopyrrolidine (6), whose crystal structure was confirmed by X-ray crystallography. Novel chiral pyrrolidine synthon 6 reacts with organosilicon (allyltrimethylsilanes and vinyloxytrimethylsilanes), organophosphorus, organozinc, and Grignard reagents to afford chiral 2-substituted and 2,5- disubstituted pyrrolidines.

A short asymmetric synthesis of 2,5-disubstituted pyrrolidines

A novel approach to chiral 2,5-disubstituted pyrrolidines, starting from chiral 2-phenyl-glycimol, 1,5-dimethoxytetrahydrofuran, and benzotriazole, involves the diastereoselective substitution by Grignard reagents of a benzotriazolyl group in a crystalline intermediate obtained in high yield.